Albany, NY, March 30, 2014 --(PR.com
)-- A new market research report by Transparency Market research sheds light on the growing scope of the Nanomedicine Market globally, and provides an in-depth analysis of the potential growth areas, restraints, region-wise revenue share, and much more.
Please visit: http://www.transparencymarketresearch.com/nanomedicine-market.html
The new title on “Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," predicts that the total nanomedicine market globally will be worth USD 177.60 billion by 2019, growing considerably from its 2012 value of USD 78.54 billion. This market is expected to achieve a compounded annual growth rate of 12.3% between 2013 and 2019.
The report talks about the major growth areas of within the nanomedicine market over the period of forecast. The introduction of new technologies and applications in this sector will propel growth to a significant degree at the global level. Further, the initiatives taken by various governments as well as privately-funded institutions towards promoting the commercialization of new nanomedicine products will boost this market. The report also dwells on the role played by the rising geriatric population base, the prevalence of medical needs that are in need of treatment, as well as the rising incidence of chronic diseases globally.
According to the report, the leading application segment within the nanomedicine market was that of oncology, holding a 38% share of the overall market in 2012, as a vast number of commercially available products prevail in this sector.
The development of nanomedicine-based treatments and products that are able to directly target tumors in the brain and other bodily sites is poised to be a significant factor affecting growth in this market.
Though the largest market segment within the nanomedicine market is that of oncology, the fastest growing segment is the cardiovascular market. According to the Transparency Market Research report, growth in this segment has been fuelled by the presence of a sizeable patient population, and a simultaneous growth in the demand for device and drugs that are based on nanomedicine. These factors are collectively anticipated to further fuel the growth of the cardiovascular segment within the nanomedicine market.
The report also carries out an in-depth analysis of the regional market share based on the applications, revenue, and products. According to the report, the nanomedicine market was largely dominated by North America in 2012. It is expected that this regional market will continue to hold its leading position in the way over the forecast period until 2019.
Though the larger market share will be held by North America, it is anticipated that the fastest growing market, by region, will be Asia-Pacific. The report states that the CAGR recorded by the Asia-Pacific market will be 14.6% between 2013 and 2019.
Furthermore, the analysis of the regional markets also concludes that the Europe region is predicted to show a growth rate that’s relatively higher than that of North America. Factors that are likely to cause this increased growth rate include: an improvement in the regulatory framework as well as the presence of a wide-ranging product portfolio in the pipeline, set to be introduced by leading market players.
The report on the global nanomedicine market additionally comprises an overview of the key market players in a section dedicated to company profiles. These key market players include names such as: Abbott Laboratories, Merck & Co Inc, Pfizer Inc., GE Healthcare, Nanosphere Inc., and many more.
To browse through the entire ToC or to purchase the report titled “Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”, please visit http://www.transparencymarketresearch.com/nanomedicine-market.html